EWA
RANI icon

EverSource Wealth Advisors’s Rani Therapeutics RANI Stock Holding History

EverSource Wealth Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-980
Closed -$490 – 4409
2025
Q3 		$490 Buy
+980
New +$511 ﹤0.01% 3957

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

EverSource Wealth Advisors's RANI Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Rani Therapeutics (RANI) in Q4 2025, closing a stake of 980 shares — an estimated $490 sold.

EverSource Wealth Advisors first reported a position in RANI in Q3 2025 and held it in 1 quarter. The position peaked at $490 in Q3 2025. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Rani Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 980 Rani Therapeutics shares in Q4 2025, an estimated $490.
  • EverSource Wealth Advisors first reported a position in Rani Therapeutics in Q3 2025 and held it in 1 quarter.
  • EverSource Wealth Advisors's Rani Therapeutics position peaked at $490 in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.